Repligen/$RGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Repligen
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Ticker
$RGEN
Sector
Primary listing
Employees
1,778
Headquarters
Website
Repligen Metrics
BasicAdvanced
$8.6B
-
-$0.25
1.08
-
Price and volume
Market cap
$8.6B
Beta
1.08
52-week high
$182.52
52-week low
$102.97
Average daily volume
934K
Financial strength
Current ratio
8.592
Quick ratio
7.038
Long term debt to equity
32.498
Total debt to equity
33.276
Interest coverage (TTM)
2.03%
Profitability
EBITDA (TTM)
119.524
Gross margin (TTM)
51.29%
Net profit margin (TTM)
-2.05%
Operating margin (TTM)
6.87%
Effective tax rate (TTM)
-1.68%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
1.12%
Return on equity (TTM)
-0.68%
Valuation
Price to revenue (TTM)
12.704
Price to book
4.16
Price to tangible book (TTM)
15.85
Price to free cash flow (TTM)
83.172
Free cash flow yield (TTM)
1.20%
Free cash flow per share (TTM)
1.835
Growth
Revenue change (TTM)
8.73%
Earnings per share change (TTM)
-249.84%
3-year revenue growth (CAGR)
-4.70%
10-year revenue growth (CAGR)
24.73%
3-year earnings per share growth (CAGR)
-55.28%
10-year earnings per share growth (CAGR)
1.08%
What the Analysts think about Repligen
Analyst ratings (Buy, Hold, Sell) for Repligen stock.
Bulls say / Bears say
Repligen reported Q2 2025 revenue of $182 million, a 15% year-over-year increase, with 17% organic growth ex-COVID across all business lines, highlighting a strong recovery in demand (Nasdaq).
Q2 orders grew over 20% sequentially, marking the eighth straight quarter where orders beat non-COVID revenue and supporting strong visibility for future backlog (Nasdaq).
In Q1 2025, Repligen acquired 908 Devices’ bioprocessing business and launched the CTech™ SoloVPE® Plus System, further strengthening its process analytics division and growth prospects (Nasdaq)
GAAP gross margin in Q2 2025 fell to 50.0%, down from 51.3% a year ago, pointing to rising cost pressures and a risk of margin erosion in the future (Globe Newswire).
Management stated new modalities would create a 1% drag on full-year revenue, revealing execution risk and limited visibility in newer market segments (Globe Newswire).
Full-year guidance factors in small tariff surcharges, suggesting exposure to changes in trade policy and risk of input cost increases (Globe Newswire).
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Repligen Financial Performance
Revenues and expenses
Repligen Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Repligen stock?
Repligen (RGEN) has a market cap of $8.6B as of October 19, 2025.
What is the P/E ratio for Repligen stock?
The price to earnings (P/E) ratio for Repligen (RGEN) stock is 0 as of October 19, 2025.
Does Repligen stock pay dividends?
No, Repligen (RGEN) stock does not pay dividends to its shareholders as of October 19, 2025.
When is the next Repligen dividend payment date?
Repligen (RGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Repligen?
Repligen (RGEN) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.